Gilead Files Once-daily Integrase Inhibitor Elvitegravir With FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Part of the Quad combination product, stand-alone elvitegravir could open up the integrase inhibitor market. In a study supporting the single-agent NDA, once-daily elvitegravir proved comparable to Merck’s twice-daily blockbuster Isentress, the only commercially available integrase inhibitor.